Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative.

Ozen S, Marks SD, Brogan P, Groot N, de Graeff N, Avcin T, Bader-Meunier B, Dolezalova P, Feldman BM, Kone-Paut I, Lahdenne P, McCann L, Pilkington C, Ravelli A, van Royen A, Uziel Y, Vastert B, Wulffraat N, Kamphuis S, Beresford MW.

Rheumatology (Oxford). 2019 Sep 1;58(9):1607-1616. doi: 10.1093/rheumatology/kez041.

PMID:
30879080
2.

Development of the Patient Experience Questionnaire for Parents of Pediatric Patients (PEQP).

Kaipio J, Karisalmi N, Hiekkanen K, Stenhammar H, Lahdenne P.

Stud Health Technol Inform. 2019;257:200-205.

PMID:
30741196
3.

The European network for care of children with paediatric rheumatic diseases: care across borders.

Dolezalova P, Anton J, Avcin T, Beresford MW, Brogan PA, Constantin T, Egert Y, Foeldvari I, Foster HE, Hentgen V, Kone-Paut I, Kuemmerle-Deschner JB, Lahdenne P, Magnusson B, Martini A, McCann L, Minden K, Ozen S, Schoemaker C, Quartier P, Ravelli A, Rumba-Rozenfelde I, Ruperto N, Vastert S, Wouters C, Zulian F, Wulffraat NM.

Rheumatology (Oxford). 2019 Jul 1;58(7):1188-1195. doi: 10.1093/rheumatology/key439.

PMID:
30668879
4.

European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides - the SHARE initiative.

de Graeff N, Groot N, Brogan P, Ozen S, Avcin T, Bader-Meunier B, Dolezalova P, Feldman BM, Kone-Paut I, Lahdenne P, Marks SD, McCann L, Pilkington C, Ravelli A, van Royen A, Uziel Y, Vastert B, Wulffraat N, Kamphuis S, Beresford MW.

Rheumatology (Oxford). 2019 Apr 1;58(4):656-671. doi: 10.1093/rheumatology/key322.

PMID:
30535249
5.

European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease - the SHARE initiative.

de Graeff N, Groot N, Ozen S, Eleftheriou D, Avcin T, Bader-Meunier B, Dolezalova P, Feldman BM, Kone-Paut I, Lahdenne P, McCann L, Pilkington C, Ravelli A, van Royen-Kerkhof A, Uziel Y, Vastert B, Wulffraat N, Kamphuis S, Brogan P, Beresford MW.

Rheumatology (Oxford). 2019 Apr 1;58(4):672-682. doi: 10.1093/rheumatology/key344.

PMID:
30535127
6.

Improving Patient Experience in a Children's Hospital: New Digital Services for Children and Their Families.

Karisalmi N, Kaipio J, Lahdenne P.

Stud Health Technol Inform. 2018;247:935-939.

PMID:
29678098
7.

Improving Hospital Services Based on Patient Experience Data: Current Feedback Practices and Future Opportunities.

Kaipio J, Stenhammar H, Immonen S, Litovuo L, Axelsson M, Lantto M, Lahdenne P.

Stud Health Technol Inform. 2018;247:266-270.

PMID:
29677964
8.

Treating juvenile idiopathic arthritis to target: recommendations of an international task force.

Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, Akikusa JD, Al-Mayouf SM, Antón J, Avcin T, Berard RA, Beresford MW, Burgos-Vargas R, Cimaz R, De Benedetti F, Demirkaya E, Foell D, Itoh Y, Lahdenne P, Morgan EM, Quartier P, Ruperto N, Russo R, Saad-Magalhães C, Sawhney S, Scott C, Shenoi S, Swart JF, Uziel Y, Vastert SJ, Smolen JS.

Ann Rheum Dis. 2018 Jun;77(6):819-828. doi: 10.1136/annrheumdis-2018-213030. Epub 2018 Apr 11.

PMID:
29643108
9.

The Finnish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR).

Lahdenne P, Aalto K, Rebane K, Vahasalo P, Putto-Laurila AK, Malin M, Kroger L, Saila H, Consolaro A, Bovis F, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO).

Rheumatol Int. 2018 Apr;38(Suppl 1):179-186. doi: 10.1007/s00296-018-3950-3. Epub 2018 Apr 7.

10.

European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative.

Groot N, de Graeff N, Marks SD, Brogan P, Avcin T, Bader-Meunier B, Dolezalova P, Feldman BM, Kone-Paut I, Lahdenne P, McCann L, Özen S, Pilkington CA, Ravelli A, Royen-Kerkhof AV, Uziel Y, Vastert BJ, Wulffraat NM, Beresford MW, Kamphuis S.

Ann Rheum Dis. 2017 Dec;76(12):1965-1973. doi: 10.1136/annrheumdis-2017-211898. Epub 2017 Sep 6.

PMID:
28877866
11.

European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative.

Groot N, de Graeff N, Avcin T, Bader-Meunier B, Brogan P, Dolezalova P, Feldman B, Kone-Paut I, Lahdenne P, Marks SD, McCann L, Ozen S, Pilkington C, Ravelli A, Royen-Kerkhof AV, Uziel Y, Vastert B, Wulffraat N, Kamphuis S, Beresford MW.

Ann Rheum Dis. 2017 Nov;76(11):1788-1796. doi: 10.1136/annrheumdis-2016-210960. Epub 2017 Jun 19.

PMID:
28630236
12.

European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative.

Groot N, de Graeff N, Avcin T, Bader-Meunier B, Dolezalova P, Feldman B, Kenet G, Koné-Paut I, Lahdenne P, Marks SD, McCann L, Pilkington CA, Ravelli A, van Royen-Kerkhof A, Uziel Y, Vastert SJ, Wulffraat NM, Ozen S, Brogan P, Kamphuis S, Beresford MW.

Ann Rheum Dis. 2017 Oct;76(10):1637-1641. doi: 10.1136/annrheumdis-2016-211001. Epub 2017 May 4. Review.

PMID:
28473426
13.

Fecal calprotectin in juvenile idiopathic arthritis patients related to drug use.

Aalto K, Lahdenne P, Kolho KL.

Pediatr Rheumatol Online J. 2017 Jan 31;15(1):9. doi: 10.1186/s12969-016-0132-2.

14.

Temporomandibular Joint Involvement in Association With Quality of Life, Disability, and High Disease Activity in Juvenile Idiopathic Arthritis.

Frid P, Nordal E, Bovis F, Giancane G, Larheim TA, Rygg M, Pires Marafon D, De Angelis D, Palmisani E, Murray KJ, Oliveira S, Simonini G, Corona F, Davidson J, Foster H, Steenks MH, Flato B, Zulian F, Baildam E, Saurenmann RK, Lahdenne P, Ravelli A, Martini A, Pistorio A, Ruperto N; Paediatric Rheumatology International Trials Organisation.

Arthritis Care Res (Hoboken). 2017 May;69(5):677-686. doi: 10.1002/acr.23003.

15.

Consensus-based recommendations for the management of juvenile dermatomyositis.

Bellutti Enders F, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, Lahdenne P, Magnusson B, Nistala K, Ozen S, Pilkington C, Ravelli A, Russo R, Uziel Y, van Brussel M, van der Net J, Vastert S, Wedderburn LR, Wulffraat N, McCann LJ, van Royen-Kerkhof A.

Ann Rheum Dis. 2017 Feb;76(2):329-340. doi: 10.1136/annrheumdis-2016-209247. Epub 2016 Aug 11. Review.

16.

[Special features of biological drug therapy in children].

Aalto K, Leinonen S, Kolho KL, Lahdenne P.

Duodecim. 2016;132(4):377-82. Review. Finnish.

PMID:
27017790
17.

Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis.

Boom V, Anton J, Lahdenne P, Quartier P, Ravelli A, Wulffraat NM, Vastert SJ.

Pediatr Rheumatol Online J. 2015 Dec 3;13:55. doi: 10.1186/s12969-015-0055-3. Review.

18.

Body composition and adipokines in patients with juvenile idiopathic arthritis and systemic glucocorticoids.

Markula-Patjas K, Valta H, Pekkinen M, Andersson S, Aalto K, Lahdenne P, Viljakainen H, Mäkitie O.

Clin Exp Rheumatol. 2015 Nov-Dec;33(6):924-30. Epub 2015 Aug 27.

PMID:
26315132
19.

Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting.

Tarkiainen M, Tynjälä P, Vähäsalo P, Lahdenne P.

Rheumatology (Oxford). 2015 Jul;54(7):1170-6. doi: 10.1093/rheumatology/keu457. Epub 2014 Dec 10.

PMID:
25504896
20.

Antibodies to decorin-binding protein B (DbpB) in the diagnosis of Lyme neuroborreliosis in children.

Sillanpää H, Skogman BH, Sarvas H, Seppälä IJ, Lahdenne P.

Int J Infect Dis. 2014 Nov;28:160-3. doi: 10.1016/j.ijid.2014.07.006. Epub 2014 Oct 12.

21.

Microbiologic findings in acute facial palsy in children.

Kanerva M, Nissinen J, Moilanen K, Mäki M, Lahdenne P, Pitkäranta A.

Otol Neurotol. 2013 Sep;34(7):e82-7. doi: 10.1097/MAO.0b013e318289844c.

PMID:
23657208
22.

Cerebrospinal fluid chemokine CXCL13 in the diagnosis of neuroborreliosis in children.

Sillanpää H, Skogman BH, Sarvas H, Seppälä IJ, Lahdenne P.

Scand J Infect Dis. 2013 Jul;45(7):526-30. doi: 10.3109/00365548.2013.776700. Epub 2013 Mar 22.

PMID:
23521134
23.

Anti-tumor necrosis factor treatment in cherubism--clinical, radiological and histological findings in two children.

Hero M, Suomalainen A, Hagström J, Stoor P, Kontio R, Alapulli H, Arte S, Toiviainen-Salo S, Lahdenne P, Mäkitie O.

Bone. 2013 Jan;52(1):347-53. doi: 10.1016/j.bone.2012.10.003. Epub 2012 Oct 12.

PMID:
23069372
24.

Prevention of infusion reactions to infliximab in paediatric patients with oral acetylsalicylic acid.

Hämäläinen A, Lahdenne P, Wikström A, Aalto K, Kolho KL.

Clin Exp Rheumatol. 2012 Jul-Aug;30(4):590-1. Epub 2012 Aug 29. No abstract available.

PMID:
22766212
25.

[Medical treatment of juvenile idiopathic arthritis].

Kröger L, Vähäsalo P, Tynjälä P, Aalto K, Säilä H, Malin M, Putto-Laurila A, Lahdenne P.

Duodecim. 2012;128(5):477-86. Review. Finnish.

PMID:
22486063
26.

Validity and predictive ability of the juvenile arthritis disease activity score based on CRP versus ESR in a Nordic population-based setting.

Nordal EB, Zak M, Aalto K, Berntson L, Fasth A, Herlin T, Lahdenne P, Nielsen S, Peltoniemi S, Straume B, Rygg M.

Ann Rheum Dis. 2012 Jul;71(7):1122-7. doi: 10.1136/annrheumdis-2011-200237. Epub 2012 Jan 17.

PMID:
22258487
27.

Decorin binding by DbpA and B of Borrelia garinii, Borrelia afzelii, and Borrelia burgdorferi sensu Stricto.

Salo J, Loimaranta V, Lahdenne P, Viljanen MK, Hytönen J.

J Infect Dis. 2011 Jul 1;204(1):65-73. doi: 10.1093/infdis/jir207.

28.

Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial.

Tynjälä P, Vähäsalo P, Tarkiainen M, Kröger L, Aalto K, Malin M, Putto-Laurila A, Honkanen V, Lahdenne P.

Ann Rheum Dis. 2011 Sep;70(9):1605-12. doi: 10.1136/ard.2010.143347. Epub 2011 May 28.

PMID:
21623000
29.

Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis.

Nordal E, Zak M, Aalto K, Berntson L, Fasth A, Herlin T, Lahdenne P, Nielsen S, Straume B, Rygg M; Nordic Study Group of Pediatric Rheumatology.

Arthritis Rheum. 2011 Sep;63(9):2809-18. doi: 10.1002/art.30426.

30.

Iron status during anti-TNF therapy in children with juvenile idiopathic arthritis.

Aalto K, Honkanen V, Lahdenne P.

Clin Rheumatol. 2011 Jan;30(1):115-9. doi: 10.1007/s10067-010-1571-7. Epub 2010 Sep 30.

PMID:
20882311
31.

Occurrence of inflammatory bowel disease in four patients with juvenile idiopathic arthritis receiving etanercept or infliximab.

Tarkiainen M, Tynjälä P, Vähäsalo P, Lahdenne P.

Scand J Rheumatol. 2011 Mar;40(2):150-2. doi: 10.3109/03009742.2010.499878. Epub 2010 Sep 26. No abstract available.

PMID:
20868307
32.

The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial.

Visvanathan S, Wagner C, Marini JC, Lovell DJ, Martini A, Petty R, Cuttica R, Woo P, Espada G, Gattorno M, Apaz MT, Baildam E, Fasth A, Gerloni V, Lahdenne P, Quartier P, Saurenmann R, Travers S, Mendelsohn A, Xu S, Giannini EH, Ruperto N; Paediatric Rheumatology INternational Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG).

Pediatr Rheumatol Online J. 2010 Sep 7;8:24. doi: 10.1186/1546-0096-8-24.

33.

The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis.

Ruperto N, Pistorio A, Ravelli A, Rider LG, Pilkington C, Oliveira S, Wulffraat N, Espada G, Garay S, Cuttica R, Hofer M, Quartier P, Melo-Gomes J, Reed AM, Wierzbowska M, Feldman BM, Harjacek M, Huppertz HI, Nielsen S, Flato B, Lahdenne P, Michels H, Murray KJ, Punaro L, Rennebohm R, Russo R, Balogh Z, Rooney M, Pachman LM, Wallace C, Hashkes P, Lovell DJ, Giannini EH, Gare BA, Martini A; Paediatric Rheumatology International Trials Organisation (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG).

Arthritis Care Res (Hoboken). 2010 Nov;62(11):1533-41. doi: 10.1002/acr.20280. Epub 2010 Jun 25.

34.

Prevention of acute adverse events related to infliximab infusions in pediatric patients.

Lahdenne P, Wikström AM, Aalto K, Kolho KL.

Arthritis Care Res (Hoboken). 2010 Jun;62(6):785-90. doi: 10.1002/acr.20246.

35.

Tumor markers AFP, CA 125, and CA 19-9 in the long-term follow-up of sacrococcygeal teratomas in infancy and childhood.

Pauniaho SL, Tatti O, Lahdenne P, Lindahl H, Pakarinen M, Rintala R, Heikinheimo M.

Tumour Biol. 2010 Aug;31(4):261-5. doi: 10.1007/s13277-010-0026-8. Epub 2010 Apr 2.

PMID:
20361286
36.

Antibody responses to borrelia IR(6) peptide variants and the C6 peptide in Swedish patients with erythema migrans.

Tjernberg I, Sillanpää H, Seppälä I, Eliasson I, Forsberg P, Lahdenne P.

Int J Med Microbiol. 2009 Aug;299(6):439-46. doi: 10.1016/j.ijmm.2008.10.006. Epub 2009 Jan 9.

PMID:
19138558
37.

Lower extremity isometric strength in children with juvenile idiopathic arthritis.

Saarinen J, Lehtonen K, Mälkiä E, Lahdenne P.

Clin Exp Rheumatol. 2008 Sep-Oct;26(5):947-53.

PMID:
19032836
38.

Improved laboratory diagnostics of Lyme neuroborreliosis in children by detection of antibodies to new antigens in cerebrospinal fluid.

Skogman BH, Croner S, Forsberg P, Ernerudh J, Lahdenne P, Sillanpää H, Seppälä I.

Pediatr Infect Dis J. 2008 Jul;27(7):605-12. doi: 10.1097/INF.0b013e31816a1e29.

PMID:
18536620
39.

Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.

Tynjälä P, Vähäsalo P, Honkanen V, Lahdenne P.

Ann Rheum Dis. 2009 Apr;68(4):552-7. doi: 10.1136/ard.2007.087130. Epub 2008 May 8.

PMID:
18467515
40.

Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis.

Tynjälä P, Kotaniemi K, Lindahl P, Latva K, Aalto K, Honkanen V, Lahdenne P.

Rheumatology (Oxford). 2008 Mar;47(3):339-44. doi: 10.1093/rheumatology/kem356. Epub 2008 Jan 31.

PMID:
18238789
41.

Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis.

Céspedes-Cruz A, Gutiérrez-Suárez R, Pistorio A, Ravelli A, Loy A, Murray KJ, Gerloni V, Wulffraat N, Oliveira S, Walsh J, Penades IC, Alpigiani MG, Lahdenne P, Saad-Magalhães C, Cortis E, Lepore L, Kimura Y, Wouters C, Martini A, Ruperto N; Pediatric Rheumatology International Trials Organization (PRINTO).

Ann Rheum Dis. 2008 Mar;67(3):309-14. Epub 2007 Sep 17.

PMID:
17875547
42.

A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.

Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, Wouters C, Silverman ED, Balogh Z, Henrickson M, Apaz MT, Baildam E, Fasth A, Gerloni V, Lahdenne P, Prieur AM, Ravelli A, Saurenmann RK, Gamir ML, Wulffraat N, Marodi L, Petty RE, Joos R, Zulian F, McCurdy D, Myones BL, Nagy K, Reuman P, Szer I, Travers S, Beutler A, Keenan G, Clark J, Visvanathan S, Fasanmade A, Raychaudhuri A, Mendelsohn A, Martini A, Giannini EH; Paediatric Rheumatology International Trials Organisation; Pediatric Rheumatology Collaborative Study Group.

Arthritis Rheum. 2007 Sep;56(9):3096-106.

43.

Antibodies to recombinant decorin-binding proteins A and B in the cerebrospinal fluid of patients with Lyme neuroborreliosis.

Panelius J, Sillanpää H, Seppälä I, Sarvas H, Lahdenne P.

Scand J Infect Dis. 2007;39(9):775-80.

PMID:
17701715
44.

Effects of infliximab on cytokines, myeloperoxidase, and soluble adhesion molecules in patients with juvenile idiopathic arthritis.

Levälampi T, Honkanen V, Lahdenne P, Nieminen R, Hakala M, Moilanen E.

Scand J Rheumatol. 2007 May-Jun;36(3):189-93.

PMID:
17657672
45.

Bone health and growth in glucocorticoid-treated patients with juvenile idiopathic arthritis.

Valta H, Lahdenne P, Jalanko H, Aalto K, Mäkitie O.

J Rheumatol. 2007 Apr;34(4):831-6. Epub 2007 Feb 15.

PMID:
17309121
46.

Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: the Pediatric Rheumatology International Trials Organization multinational quality of life cohort study.

Oliveira S, Ravelli A, Pistorio A, Castell E, Malattia C, Prieur AM, Saad-Magalhães C, Murray KJ, Bae SC, Joos R, Foeldvari I, Duarte-Salazar C, Wulffraat N, Lahdenne P, Dolezalova P, de Inocencio J, Kanakoudi-Tsakalidou F, Hofer M, Nikishina I, Ozdogan H, Hashkes PJ, Landgraf JM, Martini A, Ruperto N; Pediatric Rheumatology International Trials Organization (PRINTO).

Arthritis Rheum. 2007 Feb 15;57(1):35-43.

47.

Immune responses to borrelial VlsE IR6 peptide variants.

Sillanpää H, Lahdenne P, Sarvas H, Arnez M, Steere A, Peltomaa M, Seppälä I.

Int J Med Microbiol. 2007 Feb;297(1):45-52. Epub 2007 Jan 17.

PMID:
17234451
48.

Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis.

Tynjälä P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K.

Ann Rheum Dis. 2007 Apr;66(4):548-50. Epub 2006 Oct 26.

49.

Antigenicity of borrelial protein BBK32 fragments in early Lyme borreliosis.

Lahdenne P, Sarvas H, Kajanus R, Eholuoto M, Sillanpää H, Seppälä I.

J Med Microbiol. 2006 Nov;55(Pt 11):1499-504.

PMID:
17030908
50.

Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis.

Tynjälä P, Lahdenne P, Vähäsalo P, Kautiainen H, Honkanen V.

Ann Rheum Dis. 2006 Aug;65(8):1044-9. Epub 2006 Jan 31.

Supplemental Content

Loading ...
Support Center